Study S000561

An Open-label, Multiple-arm Study to Assess Tolerability in Participants With Overweight or Obesity, With or Without Type 2 Diabetes, When Switching From Tirzepatide to Zenagamtide

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT07868354
Study type: INTERVENTIONAL
Phase: PHASE1
Masking: NONE
Status: NOT_YET_RECRUITING
Enrollment: 60
Start: 2026-10-08
Primary completion: 2028-09-07
Lead sponsor: Novo Nordisk A/S
Conditions: Overweight; Obesity; Type 2 Diabetes
Interventions: DRUG:Tirzepatide; DRUG:Zenagamtide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1330-4403

Registered primary outcomes

Number of treatment emergent adverse events (TEAE) [From first administration of zenagamtide day 1 to day 57]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.